James Quigley
Stock Analyst at Goldman Sachs
(3.21)
Main Sectors:
8 Stocks
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
NVS Novartis | Downgrades: Sell | 119 118 | 123.7 | -4.61% | 2 | Sep 12, 2025 | |
KYMR Kymera Therapeutics | Upgrades: Overweight | 49 79 | 56.25 | 40.44% | 6 | Jun 3, 2025 | |
SNY Sanofi | Initiates Coverage On: Neutral | 65 | 45.54 | 42.73% | 1 | Mar 21, 2025 | |
MOR MorphoSys | Downgrades: Equal-Weight | n/a | n/a | n/a | 6 | Jan 19, 2024 | |
GRFS Grifols | Maintains: Neutral | 10 11 | 9.82 | 6.92% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 42 40 | 33.78 | 18.41% | 10 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 12 16 | 3.48 | 359.77% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 25 | n/a | n/a | 1 | Nov 20, 2017 |